WST Stock Overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for WST from our risk checks.
West Pharmaceutical Services, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$372.51 |
| 52 Week High | US$415.73 |
| 52 Week Low | US$206.19 |
| Beta | 1.08 |
| 1 Month Change | -5.39% |
| 3 Month Change | 2.04% |
| 1 Year Change | 46.52% |
| 3 Year Change | 38.22% |
| 5 Year Change | 201.70% |
| Change since IPO | 7,794.25% |
Recent News & Updates
Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22
West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08Recent updates
Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 14Is There Now An Opportunity In West Pharmaceutical Services, Inc. (NYSE:WST)?
Aug 31Do West Pharmaceutical Services' (NYSE:WST) Earnings Warrant Your Attention?
Aug 18West Pharmaceutical Q2 Non-GAAP EPS, revenue beats
Jul 28Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Jul 27West Pharmaceutical Services: A Great Business At A Lofty Price
Jul 06West Pharmaceutical Services, Inc. (NYSE:WST) Shares Could Be 32% Above Their Intrinsic Value Estimate
Jun 09Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
May 20Does West Pharmaceutical Services (NYSE:WST) Deserve A Spot On Your Watchlist?
May 05Healthy Dividends: Organic Growth Points North For West Pharmaceutical Services
Apr 27We Think West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt With Ease
Apr 22Should You Investigate West Pharmaceutical Services, Inc. (NYSE:WST) At US$400?
Feb 11West Pharmaceutical Services (NYSE:WST) Has A Rock Solid Balance Sheet
Jan 11West Pharmaceutical Services: Much To Admire But Risks Have Picked Up
Oct 28Why We Like The Returns At West Pharmaceutical Services (NYSE:WST)
Oct 25Here's Why I Think West Pharmaceutical Services (NYSE:WST) Is An Interesting Stock
Oct 11West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Sep 13What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Aug 02Investors Shouldn't Overlook West Pharmaceutical Services' (NYSE:WST) Impressive Returns On Capital
Jul 20West Pharmaceutical Services Stock Is Exceeding Expectations
Jul 07Do West Pharmaceutical Services's (NYSE:WST) Earnings Warrant Your Attention?
Jul 05We Think West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt With Ease
Jun 08Shareholder Returns
| WST | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.5% | -3.9% | -3.1% |
| 1Y | 46.5% | -2.9% | 15.1% |
Return vs Industry: WST exceeded the US Life Sciences industry which returned -2.9% over the past year.
Return vs Market: WST exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| WST volatility | |
|---|---|
| WST Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: WST is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: WST's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,700 | Eric Green | https://www.westpharma.com |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
West Pharmaceutical Services, Inc. Fundamentals Summary
| WST fundamental statistics | |
|---|---|
| Market Cap | US$27.51b |
| Earnings (TTM) | US$518.70m |
| Revenue (TTM) | US$2.87b |
53.0x
P/E Ratio9.6x
P/S RatioIs WST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WST income statement (TTM) | |
|---|---|
| Revenue | US$2.87b |
| Cost of Revenue | US$1.77b |
| Gross Profit | US$1.09b |
| Other Expenses | US$574.20m |
| Earnings | US$518.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.02 |
| Gross Margin | 38.13% |
| Net Profit Margin | 18.10% |
| Debt/Equity Ratio | 7.6% |
How did WST perform over the long term?
See historical performance and comparison